AD-8 for detection of dementia across a variety of healthcare settings.


Journal

The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747

Informations de publication

Date de publication:
04 03 2019
Historique:
pubmed: 5 3 2019
medline: 18 4 2019
entrez: 5 3 2019
Statut: epublish

Résumé

Dementia assessment often involves initial screening, using a brief tool, followed by more detailed assessment where required. The AD-8 is a short questionnaire, completed by a suitable 'informant' who knows the person well. AD-8 is designed to assess change in functional performance secondary to cognitive change. To determine the diagnostic accuracy of the informant-based AD-8 questionnaire, in detection of all-cause (undifferentiated) dementia in adults. Where data were available, we described the following: the diagnostic accuracy of the AD-8 at various predefined threshold scores; the diagnostic accuracy of the AD-8 for each healthcare setting and the effects of heterogeneity on the reported diagnostic accuracy of the AD-8. We searched the following sources on 27 May 2014, with an update to 7 June 2018: ALOIS (Cochrane Dementia and Cognitive Improvement Group), MEDLINE (Ovid SP), Embase (Ovid SP), PsycINFO (Ovid SP), BIOSIS Previews (Thomson Reuters Web of Science), Web of Science Core Collection (includes Conference Proceedings Citation Index) (Thomson Reuters Web of Science), CINAHL (EBSCOhost) and LILACS (BIREME). We checked reference lists of relevant studies and reviews, used searches of known relevant studies in PubMed to track related articles, and contacted research groups conducting work on the AD-8 to try to find additional studies. We developed a sensitive search strategy and used standardised database subject headings as appropriate. Foreign language publications were translated. We selected those studies which included the AD-8 to assess for the presence of dementia and where dementia diagnosis was confirmed with clinical assessment. We only included those studies where the AD-8 was used as an informant assessment. We made no exclusions in relation to healthcare setting, language of AD-8 or the AD-8 score used to define a 'test positive' case. We screened all titles generated by electronic database searches, and reviewed abstracts of potentially relevant studies. Two independent assessors checked full papers for eligibility and extracted data. We extracted data into two-by-two tables to allow calculation of accuracy metrics for individual studies. We then created summary estimates of sensitivity, specificity and likelihood ratios using the bivariate approach and plotting results in receiver operating characteristic (ROC) space. We determined quality assessment (risk of bias and applicability) using the QUADAS-2 tool. From 36 papers describing AD-8 test accuracy, we included 10 papers. We utilised data from nine papers with 4045 individuals, 1107 of whom (27%) had a clinical diagnosis of dementia. Pooled analysis of seven studies, using an AD-8 informant cut-off score of two, indicated that sensitivity was 0.92 (95% confidence interval (CI) 0.86 to 0.96); specificity was 0.64 (95% CI 0.39 to 0.82); the positive likelihood ratio was 2.53 (95% CI 1.38 to 4.64); and the negative likelihood ratio was 0.12 (95% CI 0.07 to 0.21). Pooled analysis of five studies, using an AD-8 informant cut-off score of three, indicated that sensitivity was 0.91 (95% CI 0.80 to 0.96); specificity was 0.76 (95% CI 0.57 to 0.89); the positive likelihood ratio was 3.86 (95% CI 2.03 to 7.34); and the negative likelihood ratio was 0.12 (95% CI 0.06 to 0.24).Four studies were conducted in community settings; four were in secondary care (one in the acute hospital); and one study was in primary care. The AD-8 has a higher relative sensitivity (1.11, 95% CI 1.02 to 1.21), but lower relative specificity (0.51, 95% CI 0.23 to 1.09) in secondary care compared to community care settings.There was heterogeneity across the included studies. Dementia prevalence rate varied from 12% to 90% of included participants. The tool was also used in various different languages. Among all the included studies there was evidence of risk of bias. Issues included the selection of participants, conduct of index test, and flow of assessment procedures. The high sensitivity of the AD-8 suggests it can be used to identify adults who may benefit from further specialist assessment and diagnosis, but is not a diagnostic test in itself. This pattern of high sensitivity and lower specificity is often suited to a screening test. Test accuracy varies by setting, however data in primary care and acute hospital settings are limited. This review identified significant heterogeneity and risk of bias, which may affect the validity of its summary findings.

Sections du résumé

BACKGROUND
Dementia assessment often involves initial screening, using a brief tool, followed by more detailed assessment where required. The AD-8 is a short questionnaire, completed by a suitable 'informant' who knows the person well. AD-8 is designed to assess change in functional performance secondary to cognitive change.
OBJECTIVES
To determine the diagnostic accuracy of the informant-based AD-8 questionnaire, in detection of all-cause (undifferentiated) dementia in adults. Where data were available, we described the following: the diagnostic accuracy of the AD-8 at various predefined threshold scores; the diagnostic accuracy of the AD-8 for each healthcare setting and the effects of heterogeneity on the reported diagnostic accuracy of the AD-8.
SEARCH METHODS
We searched the following sources on 27 May 2014, with an update to 7 June 2018: ALOIS (Cochrane Dementia and Cognitive Improvement Group), MEDLINE (Ovid SP), Embase (Ovid SP), PsycINFO (Ovid SP), BIOSIS Previews (Thomson Reuters Web of Science), Web of Science Core Collection (includes Conference Proceedings Citation Index) (Thomson Reuters Web of Science), CINAHL (EBSCOhost) and LILACS (BIREME). We checked reference lists of relevant studies and reviews, used searches of known relevant studies in PubMed to track related articles, and contacted research groups conducting work on the AD-8 to try to find additional studies. We developed a sensitive search strategy and used standardised database subject headings as appropriate. Foreign language publications were translated.
SELECTION CRITERIA
We selected those studies which included the AD-8 to assess for the presence of dementia and where dementia diagnosis was confirmed with clinical assessment. We only included those studies where the AD-8 was used as an informant assessment. We made no exclusions in relation to healthcare setting, language of AD-8 or the AD-8 score used to define a 'test positive' case.
DATA COLLECTION AND ANALYSIS
We screened all titles generated by electronic database searches, and reviewed abstracts of potentially relevant studies. Two independent assessors checked full papers for eligibility and extracted data. We extracted data into two-by-two tables to allow calculation of accuracy metrics for individual studies. We then created summary estimates of sensitivity, specificity and likelihood ratios using the bivariate approach and plotting results in receiver operating characteristic (ROC) space. We determined quality assessment (risk of bias and applicability) using the QUADAS-2 tool.
MAIN RESULTS
From 36 papers describing AD-8 test accuracy, we included 10 papers. We utilised data from nine papers with 4045 individuals, 1107 of whom (27%) had a clinical diagnosis of dementia. Pooled analysis of seven studies, using an AD-8 informant cut-off score of two, indicated that sensitivity was 0.92 (95% confidence interval (CI) 0.86 to 0.96); specificity was 0.64 (95% CI 0.39 to 0.82); the positive likelihood ratio was 2.53 (95% CI 1.38 to 4.64); and the negative likelihood ratio was 0.12 (95% CI 0.07 to 0.21). Pooled analysis of five studies, using an AD-8 informant cut-off score of three, indicated that sensitivity was 0.91 (95% CI 0.80 to 0.96); specificity was 0.76 (95% CI 0.57 to 0.89); the positive likelihood ratio was 3.86 (95% CI 2.03 to 7.34); and the negative likelihood ratio was 0.12 (95% CI 0.06 to 0.24).Four studies were conducted in community settings; four were in secondary care (one in the acute hospital); and one study was in primary care. The AD-8 has a higher relative sensitivity (1.11, 95% CI 1.02 to 1.21), but lower relative specificity (0.51, 95% CI 0.23 to 1.09) in secondary care compared to community care settings.There was heterogeneity across the included studies. Dementia prevalence rate varied from 12% to 90% of included participants. The tool was also used in various different languages. Among all the included studies there was evidence of risk of bias. Issues included the selection of participants, conduct of index test, and flow of assessment procedures.
AUTHORS' CONCLUSIONS
The high sensitivity of the AD-8 suggests it can be used to identify adults who may benefit from further specialist assessment and diagnosis, but is not a diagnostic test in itself. This pattern of high sensitivity and lower specificity is often suited to a screening test. Test accuracy varies by setting, however data in primary care and acute hospital settings are limited. This review identified significant heterogeneity and risk of bias, which may affect the validity of its summary findings.

Identifiants

pubmed: 30828783
doi: 10.1002/14651858.CD011121.pub2
pmc: PMC6398085
doi:

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

CD011121

Références

Arch Neurol. 2007 May;64(5):725-30
pubmed: 17502472
Cochrane Database Syst Rev. 2013 Jun 05;(6):CD003260
pubmed: 23740535
Neurologia. 2013 Mar;28(2):88-94
pubmed: 22652137
PLoS One. 2016 Dec 22;11(12):e0168949
pubmed: 28006822
Acad Emerg Med. 2011 Apr;18(4):374-84
pubmed: 21496140
Lancet. 2014 Mar 8;383(9920):911-22
pubmed: 23992774
Alzheimer Dis Assoc Disord. 2014 Apr-Jun;28(2):156-61
pubmed: 24113559
Zhonghua Nei Ke Za Zhi. 2012 Oct;51(10):777-80
pubmed: 23290975
Neurology. 2013 May 7;80(19):1778-83
pubmed: 23390181
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
J Neurovirol. 2013 Feb;19(1):109-16
pubmed: 23345074
J Formos Med Assoc. 2018 Jan;117(1):42-47
pubmed: 28336001
CMAJ. 2006 Feb 14;174(4):469-76
pubmed: 16477057
Alzheimer Dis Assoc Disord. 2009 Oct-Dec;23(4):306-14
pubmed: 19568149
ScientificWorldJournal. 2014;2014:804871
pubmed: 25436227
Neurology. 2014 Jul 22;83(4):364-73
pubmed: 24944261
Arch Neurol. 2007 May;64(5):718-24
pubmed: 17502471
Alzheimers Dement. 2013 Mar;9(2):141-50
pubmed: 23265826
BMC Med Res Methodol. 2014 May 23;14:70
pubmed: 24884381
Cochrane Database Syst Rev. 2015 Mar 10;(3):CD010772
pubmed: 25754745
Am J Alzheimers Dis Other Demen. 2011 Mar;26(2):134-8
pubmed: 21415088
Eur J Emerg Med. 2017 Dec;24(6):417-422
pubmed: 27002566
Alzheimers Res Ther. 2016 Nov 21;8(1):48
pubmed: 27866472
Cochrane Database Syst Rev. 2014 Jul 03;(7):CD010771
pubmed: 24990271
Cochrane Database Syst Rev. 2013 Mar 28;(3):
pubmed: 25177209
Alzheimer Dis Assoc Disord. 2009 Apr-Jun;23(2):117-23
pubmed: 19484913
BMJ. 2012 Dec 27;345:e8588
pubmed: 23271709
BMJ. 2015 Jun 16;350:h3029
pubmed: 26079686
Neurology. 2005 Aug 23;65(4):559-64
pubmed: 16116116
Alzheimers Dement. 2013 Jan;9(1):63-75.e2
pubmed: 23305823
Arch Neurol. 2001 Nov;58(11):1803-9
pubmed: 11708987
Brain. 2010 Nov;133(11):3290-300
pubmed: 20823087
Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003154
pubmed: 16625572
BMJ. 2010 Mar 19;340:c1425
pubmed: 20304935
Age Ageing. 2016 Jul;45(4):505-11
pubmed: 27076526
Int J Geriatr Psychiatry. 2009 Sep;24(9):895-901
pubmed: 19226529
Ann Intern Med. 2003 Jun 3;138(11):927-37
pubmed: 12779304
BMJ Open. 2018 Mar 17;8(3):e020521
pubmed: 29550782
Neurology. 1993 Feb;43(2):250-60
pubmed: 8094895
J Geriatr Psychiatry Neurol. 2015 Sep;28(3):198-202
pubmed: 25769735
Int J Geriatr Psychiatry. 2017 Oct;32(10):1072-1078
pubmed: 27526678
J Alzheimers Dis. 2015;49(1):121-7
pubmed: 26444776
Int Psychogeriatr. 2018 Aug;30(8):1189-1197
pubmed: 29223190
Arch Gerontol Geriatr. 2017 May - Jun;70:67-75
pubmed: 28088604
Fam Pract. 2018 May 23;35(3):239-246
pubmed: 29045636
Arch Intern Med. 2000 Oct 23;160(19):2964-8
pubmed: 11041904
Lancet. 2017 Dec 16;390(10113):2673-2734
pubmed: 28735855
BMJ Open. 2017 Feb 3;7(2):e011146
pubmed: 28159845
Cochrane Database Syst Rev. 2015 Oct 29;(10):CD010775
pubmed: 26513331
J Am Geriatr Soc. 2002 Mar;50(3):530-4
pubmed: 11943052
BMJ. 2005 Nov 5;331(7524):1064-5
pubmed: 16230312
Lancet. 2013 Oct 26;382(9902):1405-12
pubmed: 23871492
Rev Med Chil. 2010 Aug;138(8):1063-5
pubmed: 21140067
J Alzheimers Dis. 2013;35(1):159-68
pubmed: 23380993
Alzheimer Dis Assoc Disord. 2009 Oct-Dec;23(4):371-6
pubmed: 19561437
Neurology. 2005 Dec 27;65(12):1863-72
pubmed: 16237129
Int J Geriatr Psychiatry. 2009 Jul;24(7):748-54
pubmed: 19206079
Cochrane Database Syst Rev. 2018 Jun 18;6:CD001190
pubmed: 29923184
Lancet Public Health. 2017 Mar;2(3):e149-e156
pubmed: 29253388
Fam Pract. 2011 Jun;28(3):272-6
pubmed: 21115987
Neurology. 1984 Jul;34(7):939-44
pubmed: 6610841
ScientificWorldJournal. 2014;2014:302834
pubmed: 25548780
Am J Alzheimers Dis Other Demen. 2013 May;28(3):284-8
pubmed: 23493722
Lancet. 2005 Dec 17;366(9503):2112-7
pubmed: 16360788
Ann Emerg Med. 2011 Jun;57(6):653-61
pubmed: 20855129
Acad Emerg Med. 2013 Nov;20(11):1194-206
pubmed: 24238322
J Clin Epidemiol. 2018 Jul;99:64-74
pubmed: 29548843
Neurology. 1993 Nov;43(11):2412-4
pubmed: 8232972
PLoS Med. 2017 Mar 14;14(3):e1002247
pubmed: 28291818
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
J Am Geriatr Soc. 2004 Jul;52(7):1051-9
pubmed: 15209641
Neurology. 2006 Dec 12;67(11):1942-8
pubmed: 17159098
Age Ageing. 2018 May 01;47(3):349-355
pubmed: 29528366
Dement Geriatr Cogn Dis Extra. 2015 Sep 18;5(3):341-9
pubmed: 26483833
Cochrane Database Syst Rev. 2014 Apr 10;(4):CD010079
pubmed: 24719028
Int Psychogeriatr. 2004 Sep;16(3):275-93
pubmed: 15559753
Nihon Ronen Igakkai Zasshi. 2015;52(1):61-70
pubmed: 25786630
Am J Alzheimers Dis Other Demen. 2014 Mar;29(2):133-7
pubmed: 24277909
J Alzheimers Dis. 2011;27(1):177-85
pubmed: 21799253

Auteurs

Kirsty Hendry (K)

Institute of Cardiovascular and Medical Sciences, University of Glasgow, New Lister Building, Glasgow Royal Infirmary, Glasgow, UK, G4 OSF.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH